Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies
In order to establish a safe and reliable treatment for human immunodeficiency virus (HIV)-associated scabies, we have treated 60 episodes of scabies in this setting, occurring in 39 patients, with one of the following regimens: (i) topical treatment with benzyl benzoate solution; (ii) single-dose o...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Alberici, F. [verfasserIn] Pagani, L. [verfasserIn] Ratti, G. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Oxford, UK: Blackwell Science Ltd ; 2000 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2002 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: British journal of dermatology - Oxford : Wiley-Blackwell, 1892, 142(2000), 5, Seite 0 |
| Übergeordnetes Werk: |
volume:142 ; year:2000 ; number:5 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1046/j.1365-2133.2000.03480.x |
|---|
| Katalog-ID: |
NLEJ242137245 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ242137245 | ||
| 003 | DE-627 | ||
| 005 | 20230505191014.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120427s2000 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1046/j.1365-2133.2000.03480.x |2 doi | |
| 035 | |a (DE-627)NLEJ242137245 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a Alberici, F. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies |
| 264 | 1 | |a Oxford, UK |b Blackwell Science Ltd |c 2000 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a In order to establish a safe and reliable treatment for human immunodeficiency virus (HIV)-associated scabies, we have treated 60 episodes of scabies in this setting, occurring in 39 patients, with one of the following regimens: (i) topical treatment with benzyl benzoate solution; (ii) single-dose oral treatment with ivermectin alone; and (iii) combination therapy with benzyl benzoate solution and oral ivermectin, employing the same regimens as single-agent therapy. Patients were stratified according to the severity score of the disease and the outcome (eradication, relapse, failure). We found that both benzyl benzoate and ivermectin alone were quite effective in mild to moderate scabies, but they were both associated with an unacceptable rate of relapse and failure in severe or crusted scabies. In contrast, combined treatment produced an optimal rate of success, without significant treatment-related side-effects. Therefore, we consider that combination treatment with benzyl benzoate solution and oral ivermectin is preferable to single-agent therapy in crusted scabies occurring in HIV/acquired immune deficiency syndrome patients. | ||
| 533 | |d 2002 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2002|||||||||| | ||
| 650 | 4 | |a acquired immune deficiency syndrome | |
| 700 | 1 | |a Pagani, L. |e verfasserin |4 aut | |
| 700 | 1 | |a Ratti, G. |e verfasserin |4 aut | |
| 700 | 1 | |a Viale, P. |4 oth | |
| 773 | 0 | 8 | |i In |t British journal of dermatology |d Oxford : Wiley-Blackwell, 1892 |g 142(2000), 5, Seite 0 |h Online-Ressource |w (DE-627)NLEJ24392786X |w (DE-600)2004086-6 |x 1365-2133 |7 nnns |
| 773 | 1 | 8 | |g volume:142 |g year:2000 |g number:5 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1046/j.1365-2133.2000.03480.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 142 |j 2000 |e 5 |h 0 | ||
| author_variant |
f a fa l p lp g r gr |
|---|---|
| matchkey_str |
article:13652133:2000----::vretnlnoicmiainihezlezaenhtetetfuaimndf |
| hierarchy_sort_str |
2000 |
| publishDate |
2000 |
| allfields |
10.1046/j.1365-2133.2000.03480.x doi (DE-627)NLEJ242137245 DE-627 ger DE-627 rakwb Alberici, F. verfasserin aut Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies Oxford, UK Blackwell Science Ltd 2000 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In order to establish a safe and reliable treatment for human immunodeficiency virus (HIV)-associated scabies, we have treated 60 episodes of scabies in this setting, occurring in 39 patients, with one of the following regimens: (i) topical treatment with benzyl benzoate solution; (ii) single-dose oral treatment with ivermectin alone; and (iii) combination therapy with benzyl benzoate solution and oral ivermectin, employing the same regimens as single-agent therapy. Patients were stratified according to the severity score of the disease and the outcome (eradication, relapse, failure). We found that both benzyl benzoate and ivermectin alone were quite effective in mild to moderate scabies, but they were both associated with an unacceptable rate of relapse and failure in severe or crusted scabies. In contrast, combined treatment produced an optimal rate of success, without significant treatment-related side-effects. Therefore, we consider that combination treatment with benzyl benzoate solution and oral ivermectin is preferable to single-agent therapy in crusted scabies occurring in HIV/acquired immune deficiency syndrome patients. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| acquired immune deficiency syndrome Pagani, L. verfasserin aut Ratti, G. verfasserin aut Viale, P. oth In British journal of dermatology Oxford : Wiley-Blackwell, 1892 142(2000), 5, Seite 0 Online-Ressource (DE-627)NLEJ24392786X (DE-600)2004086-6 1365-2133 nnns volume:142 year:2000 number:5 pages:0 http://dx.doi.org/10.1046/j.1365-2133.2000.03480.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 142 2000 5 0 |
| spelling |
10.1046/j.1365-2133.2000.03480.x doi (DE-627)NLEJ242137245 DE-627 ger DE-627 rakwb Alberici, F. verfasserin aut Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies Oxford, UK Blackwell Science Ltd 2000 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In order to establish a safe and reliable treatment for human immunodeficiency virus (HIV)-associated scabies, we have treated 60 episodes of scabies in this setting, occurring in 39 patients, with one of the following regimens: (i) topical treatment with benzyl benzoate solution; (ii) single-dose oral treatment with ivermectin alone; and (iii) combination therapy with benzyl benzoate solution and oral ivermectin, employing the same regimens as single-agent therapy. Patients were stratified according to the severity score of the disease and the outcome (eradication, relapse, failure). We found that both benzyl benzoate and ivermectin alone were quite effective in mild to moderate scabies, but they were both associated with an unacceptable rate of relapse and failure in severe or crusted scabies. In contrast, combined treatment produced an optimal rate of success, without significant treatment-related side-effects. Therefore, we consider that combination treatment with benzyl benzoate solution and oral ivermectin is preferable to single-agent therapy in crusted scabies occurring in HIV/acquired immune deficiency syndrome patients. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| acquired immune deficiency syndrome Pagani, L. verfasserin aut Ratti, G. verfasserin aut Viale, P. oth In British journal of dermatology Oxford : Wiley-Blackwell, 1892 142(2000), 5, Seite 0 Online-Ressource (DE-627)NLEJ24392786X (DE-600)2004086-6 1365-2133 nnns volume:142 year:2000 number:5 pages:0 http://dx.doi.org/10.1046/j.1365-2133.2000.03480.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 142 2000 5 0 |
| allfields_unstemmed |
10.1046/j.1365-2133.2000.03480.x doi (DE-627)NLEJ242137245 DE-627 ger DE-627 rakwb Alberici, F. verfasserin aut Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies Oxford, UK Blackwell Science Ltd 2000 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In order to establish a safe and reliable treatment for human immunodeficiency virus (HIV)-associated scabies, we have treated 60 episodes of scabies in this setting, occurring in 39 patients, with one of the following regimens: (i) topical treatment with benzyl benzoate solution; (ii) single-dose oral treatment with ivermectin alone; and (iii) combination therapy with benzyl benzoate solution and oral ivermectin, employing the same regimens as single-agent therapy. Patients were stratified according to the severity score of the disease and the outcome (eradication, relapse, failure). We found that both benzyl benzoate and ivermectin alone were quite effective in mild to moderate scabies, but they were both associated with an unacceptable rate of relapse and failure in severe or crusted scabies. In contrast, combined treatment produced an optimal rate of success, without significant treatment-related side-effects. Therefore, we consider that combination treatment with benzyl benzoate solution and oral ivermectin is preferable to single-agent therapy in crusted scabies occurring in HIV/acquired immune deficiency syndrome patients. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| acquired immune deficiency syndrome Pagani, L. verfasserin aut Ratti, G. verfasserin aut Viale, P. oth In British journal of dermatology Oxford : Wiley-Blackwell, 1892 142(2000), 5, Seite 0 Online-Ressource (DE-627)NLEJ24392786X (DE-600)2004086-6 1365-2133 nnns volume:142 year:2000 number:5 pages:0 http://dx.doi.org/10.1046/j.1365-2133.2000.03480.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 142 2000 5 0 |
| allfieldsGer |
10.1046/j.1365-2133.2000.03480.x doi (DE-627)NLEJ242137245 DE-627 ger DE-627 rakwb Alberici, F. verfasserin aut Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies Oxford, UK Blackwell Science Ltd 2000 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In order to establish a safe and reliable treatment for human immunodeficiency virus (HIV)-associated scabies, we have treated 60 episodes of scabies in this setting, occurring in 39 patients, with one of the following regimens: (i) topical treatment with benzyl benzoate solution; (ii) single-dose oral treatment with ivermectin alone; and (iii) combination therapy with benzyl benzoate solution and oral ivermectin, employing the same regimens as single-agent therapy. Patients were stratified according to the severity score of the disease and the outcome (eradication, relapse, failure). We found that both benzyl benzoate and ivermectin alone were quite effective in mild to moderate scabies, but they were both associated with an unacceptable rate of relapse and failure in severe or crusted scabies. In contrast, combined treatment produced an optimal rate of success, without significant treatment-related side-effects. Therefore, we consider that combination treatment with benzyl benzoate solution and oral ivermectin is preferable to single-agent therapy in crusted scabies occurring in HIV/acquired immune deficiency syndrome patients. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| acquired immune deficiency syndrome Pagani, L. verfasserin aut Ratti, G. verfasserin aut Viale, P. oth In British journal of dermatology Oxford : Wiley-Blackwell, 1892 142(2000), 5, Seite 0 Online-Ressource (DE-627)NLEJ24392786X (DE-600)2004086-6 1365-2133 nnns volume:142 year:2000 number:5 pages:0 http://dx.doi.org/10.1046/j.1365-2133.2000.03480.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 142 2000 5 0 |
| allfieldsSound |
10.1046/j.1365-2133.2000.03480.x doi (DE-627)NLEJ242137245 DE-627 ger DE-627 rakwb Alberici, F. verfasserin aut Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies Oxford, UK Blackwell Science Ltd 2000 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In order to establish a safe and reliable treatment for human immunodeficiency virus (HIV)-associated scabies, we have treated 60 episodes of scabies in this setting, occurring in 39 patients, with one of the following regimens: (i) topical treatment with benzyl benzoate solution; (ii) single-dose oral treatment with ivermectin alone; and (iii) combination therapy with benzyl benzoate solution and oral ivermectin, employing the same regimens as single-agent therapy. Patients were stratified according to the severity score of the disease and the outcome (eradication, relapse, failure). We found that both benzyl benzoate and ivermectin alone were quite effective in mild to moderate scabies, but they were both associated with an unacceptable rate of relapse and failure in severe or crusted scabies. In contrast, combined treatment produced an optimal rate of success, without significant treatment-related side-effects. Therefore, we consider that combination treatment with benzyl benzoate solution and oral ivermectin is preferable to single-agent therapy in crusted scabies occurring in HIV/acquired immune deficiency syndrome patients. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| acquired immune deficiency syndrome Pagani, L. verfasserin aut Ratti, G. verfasserin aut Viale, P. oth In British journal of dermatology Oxford : Wiley-Blackwell, 1892 142(2000), 5, Seite 0 Online-Ressource (DE-627)NLEJ24392786X (DE-600)2004086-6 1365-2133 nnns volume:142 year:2000 number:5 pages:0 http://dx.doi.org/10.1046/j.1365-2133.2000.03480.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 142 2000 5 0 |
| source |
In British journal of dermatology 142(2000), 5, Seite 0 volume:142 year:2000 number:5 pages:0 |
| sourceStr |
In British journal of dermatology 142(2000), 5, Seite 0 volume:142 year:2000 number:5 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
acquired immune deficiency syndrome |
| isfreeaccess_bool |
false |
| container_title |
British journal of dermatology |
| authorswithroles_txt_mv |
Alberici, F. @@aut@@ Pagani, L. @@aut@@ Ratti, G. @@aut@@ Viale, P. @@oth@@ |
| publishDateDaySort_date |
2000-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ24392786X |
| id |
NLEJ242137245 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242137245</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505191014.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2000 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1046/j.1365-2133.2000.03480.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242137245</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Alberici, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Science Ltd</subfield><subfield code="c">2000</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In order to establish a safe and reliable treatment for human immunodeficiency virus (HIV)-associated scabies, we have treated 60 episodes of scabies in this setting, occurring in 39 patients, with one of the following regimens: (i) topical treatment with benzyl benzoate solution; (ii) single-dose oral treatment with ivermectin alone; and (iii) combination therapy with benzyl benzoate solution and oral ivermectin, employing the same regimens as single-agent therapy. Patients were stratified according to the severity score of the disease and the outcome (eradication, relapse, failure). We found that both benzyl benzoate and ivermectin alone were quite effective in mild to moderate scabies, but they were both associated with an unacceptable rate of relapse and failure in severe or crusted scabies. In contrast, combined treatment produced an optimal rate of success, without significant treatment-related side-effects. Therefore, we consider that combination treatment with benzyl benzoate solution and oral ivermectin is preferable to single-agent therapy in crusted scabies occurring in HIV/acquired immune deficiency syndrome patients.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2002</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2002||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">acquired immune deficiency syndrome</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pagani, L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ratti, G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Viale, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">British journal of dermatology</subfield><subfield code="d">Oxford : Wiley-Blackwell, 1892</subfield><subfield code="g">142(2000), 5, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ24392786X</subfield><subfield code="w">(DE-600)2004086-6</subfield><subfield code="x">1365-2133</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:142</subfield><subfield code="g">year:2000</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1046/j.1365-2133.2000.03480.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">142</subfield><subfield code="j">2000</subfield><subfield code="e">5</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
Alberici, F. |
| spellingShingle |
Alberici, F. misc acquired immune deficiency syndrome Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies |
| authorStr |
Alberici, F. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ24392786X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
NL |
| publishPlace |
Oxford, UK |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1365-2133 |
| topic_title |
Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies acquired immune deficiency syndrome |
| publisher |
Blackwell Science Ltd |
| publisherStr |
Blackwell Science Ltd |
| topic |
misc acquired immune deficiency syndrome |
| topic_unstemmed |
misc acquired immune deficiency syndrome |
| topic_browse |
misc acquired immune deficiency syndrome |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
p v pv |
| hierarchy_parent_title |
British journal of dermatology |
| hierarchy_parent_id |
NLEJ24392786X |
| hierarchy_top_title |
British journal of dermatology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ24392786X (DE-600)2004086-6 |
| title |
Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies |
| ctrlnum |
(DE-627)NLEJ242137245 |
| title_full |
Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies |
| author_sort |
Alberici, F. |
| journal |
British journal of dermatology |
| journalStr |
British journal of dermatology |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2000 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Alberici, F. Pagani, L. Ratti, G. |
| container_volume |
142 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
Alberici, F. |
| doi_str_mv |
10.1046/j.1365-2133.2000.03480.x |
| author2-role |
verfasserin |
| title_sort |
ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies |
| title_auth |
Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies |
| abstract |
In order to establish a safe and reliable treatment for human immunodeficiency virus (HIV)-associated scabies, we have treated 60 episodes of scabies in this setting, occurring in 39 patients, with one of the following regimens: (i) topical treatment with benzyl benzoate solution; (ii) single-dose oral treatment with ivermectin alone; and (iii) combination therapy with benzyl benzoate solution and oral ivermectin, employing the same regimens as single-agent therapy. Patients were stratified according to the severity score of the disease and the outcome (eradication, relapse, failure). We found that both benzyl benzoate and ivermectin alone were quite effective in mild to moderate scabies, but they were both associated with an unacceptable rate of relapse and failure in severe or crusted scabies. In contrast, combined treatment produced an optimal rate of success, without significant treatment-related side-effects. Therefore, we consider that combination treatment with benzyl benzoate solution and oral ivermectin is preferable to single-agent therapy in crusted scabies occurring in HIV/acquired immune deficiency syndrome patients. |
| abstractGer |
In order to establish a safe and reliable treatment for human immunodeficiency virus (HIV)-associated scabies, we have treated 60 episodes of scabies in this setting, occurring in 39 patients, with one of the following regimens: (i) topical treatment with benzyl benzoate solution; (ii) single-dose oral treatment with ivermectin alone; and (iii) combination therapy with benzyl benzoate solution and oral ivermectin, employing the same regimens as single-agent therapy. Patients were stratified according to the severity score of the disease and the outcome (eradication, relapse, failure). We found that both benzyl benzoate and ivermectin alone were quite effective in mild to moderate scabies, but they were both associated with an unacceptable rate of relapse and failure in severe or crusted scabies. In contrast, combined treatment produced an optimal rate of success, without significant treatment-related side-effects. Therefore, we consider that combination treatment with benzyl benzoate solution and oral ivermectin is preferable to single-agent therapy in crusted scabies occurring in HIV/acquired immune deficiency syndrome patients. |
| abstract_unstemmed |
In order to establish a safe and reliable treatment for human immunodeficiency virus (HIV)-associated scabies, we have treated 60 episodes of scabies in this setting, occurring in 39 patients, with one of the following regimens: (i) topical treatment with benzyl benzoate solution; (ii) single-dose oral treatment with ivermectin alone; and (iii) combination therapy with benzyl benzoate solution and oral ivermectin, employing the same regimens as single-agent therapy. Patients were stratified according to the severity score of the disease and the outcome (eradication, relapse, failure). We found that both benzyl benzoate and ivermectin alone were quite effective in mild to moderate scabies, but they were both associated with an unacceptable rate of relapse and failure in severe or crusted scabies. In contrast, combined treatment produced an optimal rate of success, without significant treatment-related side-effects. Therefore, we consider that combination treatment with benzyl benzoate solution and oral ivermectin is preferable to single-agent therapy in crusted scabies occurring in HIV/acquired immune deficiency syndrome patients. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
5 |
| title_short |
Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies |
| url |
http://dx.doi.org/10.1046/j.1365-2133.2000.03480.x |
| remote_bool |
true |
| author2 |
Pagani, L. Ratti, G. Viale, P. |
| author2Str |
Pagani, L. Ratti, G. Viale, P. |
| ppnlink |
NLEJ24392786X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| doi_str |
10.1046/j.1365-2133.2000.03480.x |
| up_date |
2024-07-06T00:58:11.453Z |
| _version_ |
1803789262079918080 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242137245</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505191014.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2000 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1046/j.1365-2133.2000.03480.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242137245</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Alberici, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Science Ltd</subfield><subfield code="c">2000</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In order to establish a safe and reliable treatment for human immunodeficiency virus (HIV)-associated scabies, we have treated 60 episodes of scabies in this setting, occurring in 39 patients, with one of the following regimens: (i) topical treatment with benzyl benzoate solution; (ii) single-dose oral treatment with ivermectin alone; and (iii) combination therapy with benzyl benzoate solution and oral ivermectin, employing the same regimens as single-agent therapy. Patients were stratified according to the severity score of the disease and the outcome (eradication, relapse, failure). We found that both benzyl benzoate and ivermectin alone were quite effective in mild to moderate scabies, but they were both associated with an unacceptable rate of relapse and failure in severe or crusted scabies. In contrast, combined treatment produced an optimal rate of success, without significant treatment-related side-effects. Therefore, we consider that combination treatment with benzyl benzoate solution and oral ivermectin is preferable to single-agent therapy in crusted scabies occurring in HIV/acquired immune deficiency syndrome patients.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2002</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2002||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">acquired immune deficiency syndrome</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pagani, L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ratti, G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Viale, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">British journal of dermatology</subfield><subfield code="d">Oxford : Wiley-Blackwell, 1892</subfield><subfield code="g">142(2000), 5, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ24392786X</subfield><subfield code="w">(DE-600)2004086-6</subfield><subfield code="x">1365-2133</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:142</subfield><subfield code="g">year:2000</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1046/j.1365-2133.2000.03480.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">142</subfield><subfield code="j">2000</subfield><subfield code="e">5</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.401087 |